QDEL Stock Analysis: QuidelOrtho | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 729m USD | 12M Return: -51.6% | US2197981051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.8M
EPS Trend: -87.0%
Qual. Beats: 0
Rev. Trend: -95.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
QuidelOrtho Corporation (NASDAQ: QDEL) is a diagnostic testing company that operates through four business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. The Labs unit provides clinical chemistry and immunoassay instruments and tests, along with disease monitoring and specialized diagnostic solutions. The Transfusion Medicine unit supplies immunohematology products for blood typing and donor screening instruments for infectious disease testing in blood and plasma. The Point of Care unit delivers rapid-result testing across various care settings, while the Molecular Diagnostics unit offers PCR thermocyclers, amplification systems, and sample-to-result instruments for syndromic infectious disease testing. The company was incorporated in 1979 and is headquartered in San Diego, California, with operations spanning North America, Europe, the Middle East, Africa, China, Japan, Asia Pacific, and Latin America.
QuidelOrtho sells its products through a direct sales force and a network of distributors, serving a broad range of customers including hospitals, clinical and reference laboratories, physician offices, urgent care clinics, blood banks, and retail outlets. As a small-cap healthcare supplies company, it operates in the in vitro diagnostics industry, which is characterized by ongoing demand for clinical testing driven by aging populations, infectious disease screening, and blood safety requirements. Its diversified business model spans hospital-based labs, donor centers, and over-the-counter settings, providing multiple channels of recurring revenue from consumable test kits and reagents.
- Sofia respiratory test demand fluctuates with flu and COVID seasons
- QuidelOrtho merger integration costs pressure near-term margins
- Transfusion Medicine segment drives recurring hospital-based revenue
| Net Income: -369.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -1.29 > 1.0 |
| NWC/Revenue: 14.61% < 20% (prev 22.06%; Δ -7.45% < -1%) |
| CFO/TA 0.00 > 3% & CFO 7.90m > Net Income -369.2m |
| Net Debt (3.10b) to EBITDA (326.9m): 9.47 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.7m) vs 12m ago 1.03% < -2% |
| Gross Margin: 44.22% > 18% (prev 47.15%; Δ -2.93% > 0.5%) |
| Asset Turnover: 45.27% > 50% (prev 47.83%; Δ -2.56% > 0%) |
| Interest Coverage Ratio: -0.66 > 6 (EBIT TTM -134.8m / Interest Expense TTM 204.3m) |
| A: 0.07 (Total Current Assets 1.45b - Total Current Liabilities 1.07b) / Total Assets 5.78b |
| B: -0.21 (Retained Earnings -1.23b / Total Assets 5.78b) |
| C: -0.02 (EBIT TTM -134.8m / Avg Total Assets 5.73b) |
| D: 0.45 (Book Value of Equity 1.79b / Total Liabilities 3.99b) |
| Altman-Z'' = 0.05 = B |
| DSRI: 0.77 (Receivables 375.5m/513.0m, Revenue 2.59b/2.71b) |
| GMI: 1.07 (GM 47.15% / 44.22%) |
| AQI: 0.99 (AQ_t 0.49 / AQ_t-1 0.50) |
| SGI: 0.96 (Revenue 2.59b / 2.71b) |
| TATA: -0.07 (NI -369.2m - CFO 7.90m) / TA 5.78b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of November 17, 2026, the stock is trading at USD 10.21 with a total of 1,942,277 shares traded. Over the past week, the price has changed by -15.55%, over one month by -20.91%, over three months by -29.97% and over the past year by -51.61%.
Current recommended Stop Loss: 8.70 (which is 14.8% or 1.2 ATR below the current price).
QuidelOrtho has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold QDEL.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 15 | 46.9% |
P/E Forward = 9.5877
P/S = 0.281
P/B = 0.4564
P/EG = 2.0638
Revenue TTM = 2.59b USD
EBIT TTM = -134.8m USD
EBITDA TTM = 326.9m USD
Long Term Debt = 2.51b USD (from longTermDebt, last quarter)
Short Term Debt = 424.4m USD (from shortTermDebt, last quarter)
Debt = 3.26b USD (from shortLongTermDebtTotal, last quarter) + Leases 179.0m
Net Debt = 3.10b USD (calculated: Debt 3.26b - CCE 166.4m)
Enterprise Value = 3.83b USD (728.7m + Debt 3.26b - CCE 166.4m)
Interest Coverage Ratio = -0.66 (Ebit TTM -134.8m / Interest Expense TTM 204.3m)
EV/FCF = -32.45x (Enterprise Value 3.83b / FCF TTM -117.9m)
FCF Yield = -3.08% (FCF TTM -117.9m / Enterprise Value 3.83b)
FCF Margin = -4.55% (FCF TTM -117.9m / Revenue TTM 2.59b)
Net Margin = -14.24% (Net Income TTM -369.2m / Revenue TTM 2.59b)
Gross Margin = 44.22% ((Revenue TTM 2.59b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 46.79% (prev 43.26%)
Tobins Q-Ratio = 0.66 (Enterprise Value 3.83b / Total Assets 5.78b)
Interest Expense / Debt = 6.26% (Interest Expense 204.3m / Debt 3.26b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -106.5m (EBIT -134.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.36 (Total Current Assets 1.45b / Total Current Liabilities 1.07b)
Debt / Equity = 1.82 (Debt 3.26b / totalStockholderEquity, last quarter 1.79b)
Debt / EBITDA = 9.47 (Net Debt 3.10b / EBITDA 326.9m)
Debt / FCF = -26.27 (negative FCF - burning cash) (Net Debt 3.10b / FCF TTM -117.9m)
Total Stockholder Equity = 1.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.45% (Net Income -369.2m / Total Assets 5.78b)
RoE = -20.13% (Net Income TTM -369.2m / Total Stockholder Equity 1.83b)
RoCE = -3.10% (EBIT -134.8m / Capital Employed (Equity 1.83b + L.T.Debt 2.51b))
RoIC = -2.13% (negative operating profit) (NOPAT -106.5m / Invested Capital 5.01b)
WACC = 6.43% (E(728.7m)/V(3.99b) * Re(13.06%) + D(3.26b)/V(3.99b) * Rd(6.26%) * (1-Tc(0.21)))
Discount Rate = 13.06% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 96.95 | Cagr: 1.05%
[DCF] Fair Price = unknown (Cash Flow -117.9m)
EPS Correlation: -86.96 | EPS CAGR: -32.21% | SUE: 0.50 | # QB: 0
Revenue Correlation: -95.51 | Revenue CAGR: -3.98% | SUE: -0.25 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.06 | Chg30d=N/A | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.67 | Chg30d=-13.93% | Revisions=-25% | GrowthEPS=-68.6% | GrowthRev=-7.7%
EPS next Year (2027-12-31): EPS=1.32 | Chg30d=-8.78% | Revisions=-40% | GrowthEPS=+97.4% | GrowthRev=-0.2%
[Analyst] Revisions Ratio: -57% (up=0, down=4)